Get the Stockscreener App
2.65
5.36%
-0.15
After Hours:
2.78
0.13
+4.91%
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Wednesday - Defense World
Aquestive Therapeutics (AQST) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Aquestive Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March - The Manila Times
Aquestive Therapeutics Sets March Conference Schedule: Key Dates for Investor Access - StockTitan
Aquestive Therapeutics' SWOT analysis: PharmFilm tech could disrupt epinephrine stock By Investing.com - Investing.com South Africa
Aquestive Therapeutics' SWOT analysis: PharmFilm tech could disrupt epinephrine stock - Investing.com India
Aquestive Therapeutics’ SWOT analysis: PharmFilm tech could disrupt epinephrine stock - Investing.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update - MarketBeat
Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET - The Manila Times
Aquestive Therapeutics to Report Fourth Quarter 2024 - GlobeNewswire
Aquestive Therapeutics Q4 Earnings: Will New Business Updates Signal Growth Momentum? - StockTitan
Leerink maintains Aquestive Outperform rating, $13 target By Investing.com - Investing.com Canada
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Drop in Short Interest - Defense World
JMP Securities maintains $9 target on Aquestive Therapeutics stock By Investing.com - Investing.com Australia
Harvey Capital Management Inc. Buys 249,790 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Target Price at $11.00 - MarketBeat
Aquestive Therapeutics Inc (NASDAQ: AQST) Is A Blank Check For Growth - Stocks Register
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) high institutional ownership speaks for itself as stock continues to impress, up 15% over last week - Simply Wall St
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $11.00 Consensus Price Target from Analysts - MarketBeat
Aquestive Therapeutics to Present New Findings on Anaphylm™ - GlobeNewswire
Aquestive Therapeutics Announces Positive Stability and Efficacy Data for Anaphylm Epinephrine Sublingual Film at AAAAI Annual Meeting - Nasdaq
Breakthrough Allergy Treatment Shows 12-Min Response Time: Aquestive's Game-Changing Phase 2 Results - StockTitan
SG Americas Securities LLC Grows Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Wall Street analysts’ outlook for Aquestive Therapeutics Inc (AQST) - SETE News
Aquestive Therapeutics Inc [AQST] stock for 214 USD was sold by Jung Cassie - Knox Daily
Aquestive Therapeutics Inc (AQST) expanding its growth trajectory ahead - SETE News
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Significant Increase in Short Interest - MarketBeat
Epilepsy Market Expected to rise, 2034 | Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven - Barchart
Did Aquestive Therapeutics Inc (AQST) perform well in the last session? - US Post News
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference - GlobeNewswire
Piper starts Aquestive at overweight, cites allergy reaction treatment - MSN
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates - MSN
Institutional investors own a significant stake of 49% in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Yahoo Finance
Cantor Fitzgerald Weighs in on AQST FY2025 Earnings - MarketBeat
Head to Head Survey: Aquestive Therapeutics (NASDAQ:AQST) & Vistagen Therapeutics (NASDAQ:VTGN) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Up 8.6% in December - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Barclays PLC - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Anaphylaxis Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight | Aravax Pty Ltd, AstraZeneca, Aquestive Therapeutics - Barchart
Neuromuscular Disease Therapeutics Market to grow by USD 13.7 Billion from 2025-2029, driven by novel approvals, with AI impacting market trendsTechnavio - The Malaysian Reserve
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Neuromuscular Disease Therapeutics Market to Grow by USD 13.73 Billion from 2025-2029, Driven by Novel Approvals and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Aquestive Therapeutics Updates on Strategic Goals and Drug Progress - TipRanks
1.25%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):